Supernus Pharmaceuticals Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Supernus Pharmaceuticals Stock Summary

Supernus Pharmaceuticals competes with Prestige Brand, Evotec SE, Collegium Pharmaceutical, ANI Pharmaceuticals, and Phibro Animal. Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company was incorporated in 2005 and is headquartered in Rockville, Maryland. Supernus Pharm operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 603 people.

Supernus Pharmaceuticals Key Financial Ratios

Supernus Pharmaceuticals Key Balance Sheet Accounts

Supernus Pharmaceuticals Key Income Statement Accounts

Supernus Pharmaceuticals Key Cash Accounts

Supernus Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Supernus Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Supernus Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Supernus Pharmaceuticals competition to find correlations between indicators driving Supernus Pharmaceuticals's intrinsic value. More Info.Supernus Pharmaceuticals is rated fourth in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about  0.38  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Supernus Pharmaceuticals is roughly  2.60 . At this time, Supernus Pharmaceuticals' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Supernus Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Supernus Pharmaceuticals Systematic Risk

Today, most investors in Supernus Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Supernus Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Supernus Pharmaceuticals growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Supernus Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Supernus Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Supernus Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Supernus Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Supernus Pharmaceuticals's daily price indicators and compare them against related drivers.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.